Tumour suppressor genes in sporadic epithelial ovarian cancer

Reproduction

Volumn 123, Issue 3, 2002, Pages 341-353

  Liu, Ying ^a   Ganesan, Trivadi S ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HOMEODOMAIN PROTEIN; NUCLEAR PROTEIN; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN P16; PROTEIN P53; RAS PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 13Q; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 18Q; CHROMOSOME 19P; CHROMOSOME 6; CHROMOSOME 9P; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GYNECOLOGIC CANCER; HETEROZYGOSITY LOSS; HUMAN; IDIOPATHIC DISEASE; MOLECULAR CLONING; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; X CHROMOSOME;

EID: 0036122711     PISSN: 14701626     EISSN: None     Source Type: Journal    
DOI: 10.1530/rep.0.1230341     Document Type: Review

References (131)

1. Genes involved in hereditary nonpolyposis colorectal carcinoma
2. LOT1 is a growth suppressor gene downregulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein
3. Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22
4. The biology of ovarian cancer
5. Our genome unveiled
6. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma
7. Alterations in DNA methylation: A fundamental aspect of neoplasia
8. Allelic loss on chromosome arm 8p: Analysis of sporadic epithelial ovarian tumors
9. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors
10. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells
11. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q
12. Non-surgical aspects of ovarian cancer
13. Emerging molecular cytogenetic technologies
14. Risk factors for epithelial ovarian cancer in Beijing, China
15. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinico-pathological correlations
16. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas
17. Human epithelial ovarian cancer allelotype
18. A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas
19. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer
20. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer
21. Pten is essential for embryonic development and tumour suppression
22. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers
23. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus
24. Allele losses on chromosome 17 in human epithelial ovarian carcinoma
25. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors
26. Disabled-2 inactivation is an early step in ovarian tumorigenicity
27. The murine gene p27Kip1 is haplo-insufficient for tumour suppression
28. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
29. Mutation analysis of RASK and the 'FLR exon' of NF1 in sporadic ovarian carcinoma
30. Prognostic factors
31. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer
32. Cancer and genomics
33. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis
34. Spontaneous transformation of rat ovarian surface epithelial cells: Association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer
35. Oncogenes and tumour suppresor genes
36. Tumour-suppressor genes: Evolving definitions in the genomic age
37. Clinical implications of the p53 tumor-suppressor gene
38. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
39. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer
40. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target
41. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
42. Genetic analysis of benign, low-grade, and high-grade ovarian tumors
43. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors
44. Cancer epigenetics comes of age
45. Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors
46. A cell cycle regulator potentially involved in genesis of many tumor types
47. Molecular approaches to diagnosis and management of ovarian cancer
48. You don't need a backbone to carry a tumour suppressor gene
49. Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus
50. Adenovirus-mediated transfer of a p53 gene in ovarian cancer
51. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse
52. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression
53. Antioncogenes and human cancer
54. Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer
55. Ovarian cancer: Loss of heterozygosity frequently occurs in the ATM gene, but structural alterations do not occur in this gene
56. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas
57. Brca2 mutations in primary breast and ovarian cancers
58. Chromosome 11q22.3-q25 LOH in ovarian cancer: Association with a more aggressive disease course and involved subregions
59. ATM: The product of the gene mutated in ataxia-telangiectasia
60. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
61. Frequent silencing of the GPC3 gene in ovarian cancer cell lines
62. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer
63. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas
64. Hereditary ovarian cancer. Heterogeneity in age at onset
65. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13)
66. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site
67. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice
68. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
69. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer
70. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer
71. CDKN2A gene inactivation in epithelial sporadic ovarian cancer
72. Mutational analysis of STK11 gene in ovarian carcinomas
73. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors
74. Allelic imbalance of chromosome 6q in ovarian tumours
75. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D
76. WWOX: A candidate tumor suppressor gene involved in multiple tumor types
77. Epithelial ovarian cancer: Prevention, diagnosis, and treatment Ca-A
78. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics
79. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers
80. Allelic deletion on chromosome 17p13.3 in early ovarian cancer
81. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
82. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and downregulated by wild-type p53
83. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours
84. Comparing species
85. Allele loss from chromosome 17 in ovarian cancer
86. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors
87. Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers
88. Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27
89. A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells
90. Allelotype of human ovarian cancer
91. Multicolor spectral karyotyping of human chromosomes
92. Identification of two candidate tumor suppressor genes on chromosome 17p13.3
93. Comparison of fluorescence-based semi-automated genotyping of multiple microsatellite loci with autoradiographic techniques
94. BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression
95. PIK3CA is implicated as an oncogene in ovarian cancer
96. The genetic analysis of ovarian cancer
97. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours
98. No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms
99. Immuno-histochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors
100. A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer
101. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
102. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction
103. Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer
104. Mutation of K-RAS proto-oncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas
105. Mutation analysis of the BRCA1 gene in ovarian cancers
106. Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers
107. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer
108. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity
109. Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21
110. Early involvement of 6q in surface epithelial ovarian tumors
111. Physical map of the D6S149-D6S193 region on chromosome 6Q27 and its involvement in benign surface epithelial ovarian tumours
112. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping
113. Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: Identification of loss-of-function mutations in the GPC3 gene
114. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors
115. Specific cytogenetic changes in ovarian cancer involving chromosomes 6 and 14
116. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3
117. Three distinct regions of chromosome 6 are targets of loss of heterozygosity in human ovarian carcinomas
118. Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25
119. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours
120. Drosophila in cancer research: The first fifty tumor suppressor genes
121. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis
122. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors
123. Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers
124. Identification of the breast cancer susceptibility gene BRCA2
125. Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product
126. Identifying tumor suppressors in genetic mosaics: The Drosophila lats gene encodes a putative protein kinase
127. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2
128. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas
129. Targeting frequency for deletion vectors in embryonic stem cells